Advanced Breast Cancer Clinical Trial
Official title:
Efficacy and Safety of Metronomic Pegylated Liposomal Doxorubicin in Patients With Primary Endocrine Resistant Advanced Breast Cancer
Verified date | April 2022 |
Source | Fudan University |
Contact | Xichun Hu, MD, PhD |
Phone | 64175590 |
huxicun[@]gmail.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Metronomic PLD in Patients with Primary Endocrine Resistant ABC
Status | Recruiting |
Enrollment | 46 |
Est. completion date | December 1, 2022 |
Est. primary completion date | December 1, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Females with age between 18 and 75 years old 2. ECOG: 0~2 3. Life expectancy longer than 3 months 4. Histological proven unresectable recurrent or metastatic HR positive/HER2 negative breast cancer 5. Primary endocrine resistance is defined as: a relapse while on the first 2 years of adjuvant ET, or PD within first 6 months of first-line ET for MBC, while on ET 6. At least one measurable disease according to RECIST 1.1(except for bone metastasis only) 7. LVEF = 55% 8. No radiation therapy within 4 weeks prior to enrollment 9. Normal function of major organs: Hb = 90 g/L (no blood transfusion within 14 days) ;ANC =1.5×109 /L;PLT =75×109 /L;TBIL=1. 5×ULN; ALT? AST= 3×ULN(ALT? AST= 5×ULN with hepatic metastases); serum Cr = 1×ULN 10. Be willing to participate in the study, sign informed consent and cooperate with the follow-up Exclusion Criteria: 1. Previous accumulated or equivalent dose of doxorubicin =300mg/m2 2. Intervals of anthracycline-based adjuvant chemotherapy =1 year (time between anthracycline-based adjuvant or neoadjuvant chemotherapy and disease relapse) 3. Patients with symptomatic central nervous system metastases. Except for patients with stable and asymptomatic brain metastases for at least 8 weeks and no need for glucocorticoids or mannitol treatment before the trial and at least one measurable lesion outside the brain. Radiotherapy for brain metastases should be completed at least 4 weeks before the registration 4. Pregnant or lactating women and gestational age women who are unable to use effective contraception 5. Treatment with investigational products within 4 weeks before the study 6. Severe cardiopulmonary insufficiency, severe hepatic and renal dysfunction 7. Severe or uncontrolled infection 8. Psychiatric drugs abuse and unable to withdrawal or mental disorders 9. Other malignancies, except for cured skin basal cell carcinoma and cervical intraepithelial neoplasia. |
Country | Name | City | State |
---|---|---|---|
China | Fudan University Cancer Hospital | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Fudan University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PFS | Progression Free Survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | |
Secondary | Number and grade of treatment-related cardiotoxicity as assessed by CTCAE v4.0 | monitoring LVEF | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | |
Secondary | OS | Overall Survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | |
Secondary | CBR | Clinical Benefit Rate | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04653740 -
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
|
N/A | |
Completed |
NCT02091960 -
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05156619 -
Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
|
||
Recruiting |
NCT05173103 -
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
|
||
Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
Completed |
NCT00754325 -
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
|
Phase 2 | |
Recruiting |
NCT04953377 -
PFMT Educational Intervention for Patients With Advancer Breast Cancer
|
N/A | |
Completed |
NCT03240224 -
Bioinformation Therapy for Breast Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT06193525 -
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
|
Phase 2 | |
Completed |
NCT03312738 -
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
|
Phase 2 | |
Active, not recruiting |
NCT05063786 -
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
|
Phase 3 | |
Recruiting |
NCT05655598 -
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02499146 -
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT00445458 -
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04456855 -
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
|
||
Completed |
NCT04408118 -
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
|
Phase 2 | |
Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT03205761 -
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT04316169 -
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT00546104 -
Phase II Dasatinib Study in Advanced Breast Cancer
|
Phase 2 |